AMA Supports Clinically Appropriate Use of Next-Generation Genome Sequencing | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

AMA Supports Clinically Appropriate Use of Next-Generation Genome Sequencing

November 13, 2012
by Gabriel Perna
| Reprints

Chicago-based physician advocacy group, the American Medical Association (AMA) had a policy-making meeting this week and recognized the ability to integrate next-generation genome sequencing technologies into a clinical setting. The AMA said it supports “regulatory policy that protects patient rights and confidentiality, and enables physicians to access and use such diagnostic tools as clinically appropriate.”

“Advances in DNA sequencing technology offer patients and physicians a new diagnostic tool to help improve health outcomes, but clinical challenges must be addressed to realize the full potential benefits of this technology,” AMA Board Member Robert M. Wah, M.D., said in a statement

“While cost and time barriers to genetic sequencing have been reduced, important privacy, practice, payment and regulatory issues, including how to compensate physicians and other health care professionals for the considerable work-related demands required, must still be addressed.”  AMA also supports policy that informs and educates physicians and trainees on the clinical uses of these technologies.

In addition, the AMA supported policy that calls on the Centers for Medicare & Medicaid Services (CMS) to suspend the implementation of the ICD-10 code set. According to a report from American Medical News, one AMA delegate said the group will continue to fight for physicians when it comes to being over-burdened by the ICD-10 regulatory requirement.

The Health IT Summits gather 250+ healthcare leaders in cities across the U.S. to present important new insights, collaborate on ideas, and to have a little fun - Find a Summit Near You!


See more on

betebettipobetngsbahis bahis siteleringsbahis